SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
SRX Global Says UC Davis Activated As Clinical Trial Site For CERTAIN-T, Ongoing Phase 1 Study Evaluating CER-1236 In Patients With Hematologic Malignancies Being Conducted By CERo Therapeutics
SRX Global Inks Stock Purchase Agreement With Cero Therapeutics; To Acquire All Outstanding Stock Of Cero Therapeutics
SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim
SRX Global Announces $1.5M Commitment To Roll Out New Family Of Actively Managed ETFs
SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
SRX Global Inc (SRXH) (Q3 2026) Earnings Call Highlights: Strategic EMJX Acquisition and Record ...
SRX HealthSolutions Q3 2026 Earnings Call: Complete Transcript
SRX HealthSolutions Q3 EPS $(0.36) Up From $(44.51) YoY, Sales $3.392M Up From $2.673M YoY
SRX Global to Host Fiscal Third Quarter 2026 Conference Call on August 13 at 4:30 p.m. ET
SRX Global (SRXH) Acquires Stake in Vistagen Therapeutics
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
SRX Global Portfolio Company Smartkem, Inc. (NASDAQ: SMTK) Announces Merger
SRX Global Regains Full Compliance with NYSE American Listing Standards
SRX Global Reports 26% Returns From Paper-Traded EMJX From Feb. 11 To July 10
SRXH Stock Falls Premarket Ahead Of Eric Jackson's Fireside Chat — Traders Brace For Buyback Clues And CEO Spotlight
SRX Global Management Team to Host Virtual Fireside Chat on July 14, 2026, and Issues Letter to Shareholders
SRX Global Board of Directors Authorizes Stock Repurchase Plan of Up to 10 Million Shares or Up to 50% of its Shares Outstanding
SRX Global Authorizes $20M Share Buyback Program For Up To 10M Shares, Or 50% Of Outstanding Stock
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.